论文部分内容阅读
目的观察肥胖T2DM患者联合应用格列美脲的临床疗效。方法选取76例血糖控制不佳的肥胖T2DM患者随机分为对照组和治疗组(联用格列美脲),进行12周临床观察。结果两组平均HbA_1c及空腹血糖、餐后血糖均显著下降,治疗组下降更为显著;治疗组空腹胰岛素(FIns)和HO-MA-IR较治疗前下降,体重、BMI及胰岛素用量均显著减少;治疗组有1例患者发生一般性低血糖事件1次,无其他不良反应。结论对于血糖控制不佳的肥胖T2DM患者早期联用格列美脲,可有效降低患者空腹血糖及餐后血糖水平,有利于患者实现HbA_1c达标;同时可显著降低胰岛素用量,提高治疗安全性和耐受性。
Objective To observe the clinical efficacy of glimepiride in patients with obesity T2DM. Methods 76 obese T2DM patients with poor glycemic control were randomly divided into control group and treatment group (with glimepiride) for 12 weeks. Results The average HbA_1c, fasting blood glucose and postprandial blood glucose were significantly decreased in both groups, and the decrease was more significant in the treatment group. The fasting insulin (FIns) and HO-MA-IR in the treatment group were significantly lower than those before treatment, while the body weight, BMI and insulin dosage were significantly decreased ; 1 patient in the treatment group had a general hypoglycemic event once and no other adverse reactions. Conclusions Early administration of glimepiride in obese T2DM patients with poor glycemic control can effectively reduce fasting blood glucose and postprandial blood glucose levels in patients with HbA1c, and can significantly reduce the dosage of insulin and improve the safety and tolerability of T2DM patients By sexual.